Clinical trial
DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV…
NCT00005091 · Daiichi Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00005091 |
|---|---|
| Title | DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
| Official title | A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer as First Line Therapy |
| Lead sponsor | Daiichi Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | exatecan mesylate |
| Start date | Feb 1, 1999 |
| Completion | Aug 1, 2003 |
| First posted | Jun 8, 2004 |
| Last update posted | Jul 10, 2013 |
| Countries | Finland, Germany, Italy, Netherlands, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: